About New England Nuclear (NASDAQ:LNTH)
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LNTH
CUSIPN/A
Phone978-671-8001
Debt
Debt-to-Equity Ratio11.40%
Current Ratio3.16%
Quick Ratio2.60%
Price-To-Earnings
Trailing P/E Ratio17.35
Forward P/E Ratio16.68
P/E Growth1.4
Sales & Book Value
Annual Sales$331.38 million
Price / Sales1.98
Cash Flow$1.5603 per share
Price / Cash11.12
Book Value$0.62 per share
Price / Book27.98
Profitability
EPS (Most Recent Fiscal Year)$1.00
Net Income$123.38 million
Net Margins37.23%
Return on Equity-68.13%
Return on Assets14.00%
Miscellaneous
Employees483
Outstanding Shares37,860,000
New England Nuclear (NASDAQ:LNTH) Frequently Asked Questions
What is New England Nuclear's stock symbol?
New England Nuclear trades on the NASDAQ under the ticker symbol "LNTH."
How were New England Nuclear's earnings last quarter?
New England Nuclear Co. (NASDAQ:LNTH) issued its quarterly earnings results on Monday, February, 26th. The medical equipment provider reported $0.12 EPS for the quarter, missing the consensus estimate of $0.20 by $0.08. The medical equipment provider had revenue of $81.24 million for the quarter, compared to analyst estimates of $78.57 million. New England Nuclear had a negative return on equity of 68.13% and a net margin of 37.23%. The business's revenue for the quarter was up 9.3% on a year-over-year basis. During the same period last year, the company posted $0.18 EPS. View New England Nuclear's Earnings History.
What price target have analysts set for LNTH?
4 analysts have issued 12 month price objectives for New England Nuclear's stock. Their forecasts range from $22.00 to $27.00. On average, they expect New England Nuclear's stock price to reach $24.00 in the next year. View Analyst Ratings for New England Nuclear.
Are investors shorting New England Nuclear?
New England Nuclear saw a decrease in short interest in the month of April. As of April 13th, there was short interest totalling 603,894 shares, a decrease of 36.8% from the March 30th total of 955,433 shares. Based on an average daily trading volume, of 338,114 shares, the short-interest ratio is presently 1.8 days. Approximately 1.7% of the company's shares are sold short.
Who are some of New England Nuclear's key competitors?
Some companies that are related to New England Nuclear include Quidel (QDEL), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Quotient (QTNT), Trinity Biotech (TRIB), Vermillion (VRML), Celldex Therapeutics (CLDX), AspenBio Pharma (RIOT), Akers Biosciences (AKER), ImmuCell (ICCC), Achieve Life Sciences (ACHV) and Genenews (GNWSF).
Who are New England Nuclear's key executives?
New England Nuclear's management team includes the folowing people:
- Ms. Mary Anne Heino, CEO, Pres & Director (Age 58)
- Mr. John W. Crowley, CFO & Treasurer (Age 54)
- Mr. Michael P. Duffy, Sr. VP of Strategy & Bus. Devel., Gen. Counsel and Sec. (Age 57)
- Mr. Timothy G. Healey, Sr. VP of Commercial (Age 52)
- Mr. William C. Dawes Jr., VP of Manufacturing and Operations (Age 46)
When did New England Nuclear IPO?
(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.
Has New England Nuclear been receiving favorable news coverage?
Media headlines about LNTH stock have trended somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. New England Nuclear earned a media sentiment score of 0.09 on Accern's scale. They also assigned news coverage about the medical equipment provider an impact score of 44.63 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of New England Nuclear?
Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is New England Nuclear's stock price today?
One share of LNTH stock can currently be purchased for approximately $17.35.
How big of a company is New England Nuclear?
New England Nuclear has a market capitalization of $666.35 million and generates $331.38 million in revenue each year. The medical equipment provider earns $123.38 million in net income (profit) each year or $1.00 on an earnings per share basis. New England Nuclear employs 483 workers across the globe.
How can I contact New England Nuclear?
New England Nuclear's mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]
MarketBeat Community Rating for New England Nuclear (LNTH)
MarketBeat's community ratings are surveys of what our community members think about New England Nuclear and other stocks. Vote "Outperform" if you believe LNTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
New England Nuclear (NASDAQ:LNTH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for New England Nuclear in the last 12 months. Their average twelve-month price target is $24.00, suggesting that the stock has a possible upside of 38.33%. The high price target for LNTH is $27.00 and the low price target for LNTH is $22.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.75 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $24.00 | $24.00 | $24.00 | $18.75 |
| Price Target Upside: | 38.33% upside | 6.19% upside | 6.19% upside | 0.27% upside |
New England Nuclear (NASDAQ:LNTH) Consensus Price Target History
New England Nuclear (NASDAQ:LNTH) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
New England Nuclear (NASDAQ:LNTH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
New England Nuclear (NASDAQ LNTH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.20%
Institutional Ownership Percentage: 89.94%
New England Nuclear (NASDAQ LNTH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/3/2018 | Michael P Duffy | Insider | Sell | 27,313 | $15.30 | $417,888.90 | 191,472 |  |
| 3/14/2018 | Michael P Duffy | Insider | Sell | 11,492 | $16.60 | $190,767.20 | | |
| 2/26/2018 | Timothy G Healey | SVP | Sell | 3,696 | $19.58 | $72,367.68 | 64,582 | |
| 1/16/2018 | John W Crowley | CFO | Sell | 3,866 | $23.52 | $90,928.32 | | |
| 1/10/2018 | Michael P Duffy | Insider | Sell | 21,655 | $22.40 | $485,072.00 | 156,784 | |
| 11/17/2017 | Timothy G Healey | SVP | Sell | 11,314 | $21.51 | $243,364.14 | | |
| 11/14/2017 | Michael P Duffy | Insider | Sell | 11,917 | $21.63 | $257,764.71 | 152,301 | |
| 10/13/2017 | John W Crowley | CFO | Sell | 6,755 | $18.41 | $124,359.55 | | |
| 9/13/2017 | Derace L Schaffer | Director | Sell | 15,000 | $17.50 | $262,500.00 | 48,730 | |
| 9/11/2017 | Michael P Duffy | Insider | Sell | 20,000 | $16.45 | $329,000.00 | 184,218 | |
| 9/7/2017 | David F Burgstahler | Director | Sell | 102,958 | $16.56 | $1,704,984.48 | 13,248 | |
| 9/6/2017 | David F Burgstahler | Director | Sell | 78,833 | $16.95 | $1,336,219.35 | 13,248 | |
| 9/5/2017 | Cesare Orlandi | Insider | Sell | 18,000 | $16.69 | $300,420.00 | 87,078 | |
| 9/5/2017 | David F Burgstahler | Director | Sell | 52,010 | $17.08 | $888,330.80 | 13,248 | |
| 9/1/2017 | David F Burgstahler | Director | Sell | 6,000 | $17.10 | $102,600.00 | 13,248 | |
| 8/31/2017 | David F Burgstahler | Director | Sell | 230,685 | $17.25 | $3,979,316.25 | 13,248 | |
| 8/28/2017 | David F Burgstahler | Director | Sell | 91,166 | $17.01 | $1,550,733.66 | 13,248 | |
| 8/16/2017 | Avista Capital Partners Gp, Ll | Major Shareholder | Sell | 12,128 | $17.05 | $206,782.40 | | |
| 8/16/2017 | David F Burgstahler | Director | Sell | 140,846 | $17.27 | $2,432,410.42 | 13,248 | |
| 8/15/2017 | Avista Capital Partners Gp, Ll | Major Shareholder | Sell | 40,779 | $17.06 | $695,689.74 | | |
| 8/14/2017 | Avista Capital Partners Gp, Ll | Major Shareholder | Sell | 87,939 | $17.40 | $1,530,138.60 | | |
| 7/12/2017 | Mary Anne Heino | CEO | Sell | 10,000 | $18.05 | $180,500.00 | 592,468 | |
| 6/20/2017 | David F Burgstahler | Director | Sell | 3,000,000 | $14.87 | $44,610,000.00 | | |
| 6/12/2017 | Mary Anne Heino | CEO | Sell | 10,000 | $15.39 | $153,900.00 | 602,468 | |
| 6/12/2017 | Michael P Duffy | Insider | Sell | 20,000 | $15.42 | $308,400.00 | 188,234 | |
| 5/10/2017 | Derace L Schaffer | Director | Sell | 10,000 | $15.75 | $157,500.00 | 63,730 | |
| 5/9/2017 | Avista Capital Partners Gp, Ll | Major Shareholder | Sell | 3,000,000 | $13.40 | $40,200,000.00 | | |
| 5/9/2017 | Derace L Schaffer | Director | Sell | 10,000 | $14.75 | $147,500.00 | 73,730 | |
| 3/17/2017 | David F Burgstahler | Director | Sell | 3,000,000 | $12.20 | $36,600,000.00 | | |
| 11/21/2016 | David F Burgstahler | Director | Sell | 2,500,000 | $9.00 | $22,500,000.00 | | |
(Data available from 1/1/2013 forward)
New England Nuclear (NASDAQ LNTH) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | New England Nuclear (LNTH) versus Its Competitors Financial Contrast
www.americanbankingnews.com - April 24 at 7:24 PM |
| New England Nuclear Co. (LNTH) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 24 at 1:30 AM |
| Critical Review: New England Nuclear (LNTH) & Its Rivals
www.americanbankingnews.com - April 23 at 7:18 PM |
| Reviewing New England Nuclear (LNTH) & The Competition
www.americanbankingnews.com - April 20 at 11:14 PM |
| New England Nuclear (LNTH) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 19 at 8:31 PM |
 | Lantheus Holdings to Host First Quarter 2018 Earnings Conference Call on May 2, 2018 at 4:30 p.m. Eastern Time
finance.yahoo.com - April 18 at 4:42 PM |
| Head-To-Head Comparison: New England Nuclear (LNTH) & The Competition
www.americanbankingnews.com - April 18 at 1:20 AM |
| New England Nuclear (LNTH) Coverage Initiated at Cantor Fitzgerald
www.americanbankingnews.com - April 17 at 11:58 PM |
| New England Nuclear (LNTH) & Its Competitors Head to Head Survey
www.americanbankingnews.com - April 17 at 9:14 PM |
| New England Nuclear (LNTH) Receives "Buy" Rating from Jefferies Group
www.americanbankingnews.com - April 14 at 10:17 AM |
| New England Nuclear (LNTH) PT Raised to $19.00
www.americanbankingnews.com - April 14 at 9:09 AM |
| New England Nuclear Co. (LNTH) Short Interest Up 51.9% in March
www.americanbankingnews.com - April 14 at 1:41 AM |
| Zacks Investment Research Upgrades New England Nuclear (LNTH) to Strong-Buy
www.americanbankingnews.com - April 13 at 1:35 PM |
| Critical Comparison: New England Nuclear (LNTH) and Achieve Life Sciences (ACHV)
www.americanbankingnews.com - April 12 at 5:27 PM |
| Critical Comparison: New England Nuclear (LNTH) and The Competition
www.americanbankingnews.com - April 9 at 7:21 PM |
| Michael P. Duffy Sells 27,313 Shares of Lantheus Holdings Inc (LNTH) Stock
www.americanbankingnews.com - April 5 at 7:14 PM |
| Lantheus (LNTH) Lowered to Hold at ValuEngine
www.americanbankingnews.com - April 3 at 12:11 PM |
| Head to Head Review: Lantheus (LNTH) and Its Peers
www.americanbankingnews.com - April 2 at 1:16 PM |
| Lantheus (LNTH) Upgraded to Outperform at Wells Fargo
www.americanbankingnews.com - April 2 at 8:22 AM |
| Lantheus (LNTH) Upgraded to Strong-Buy by Zacks Investment Research
www.americanbankingnews.com - April 1 at 6:28 PM |
| Zacks Investment Research Lowers Lantheus (LNTH) to Hold
www.americanbankingnews.com - March 31 at 11:00 PM |
| Lantheus (LNTH) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - March 30 at 11:10 PM |
| Lantheus (LNTH) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 30 at 8:24 PM |
| Lantheus Holdings Inc (LNTH) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 30 at 1:32 AM |
| Lantheus (LNTH) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - March 28 at 10:44 AM |
| Lantheus (LNTH) Upgraded by TheStreet to "C-"
www.americanbankingnews.com - March 21 at 1:10 PM |
| Lantheus Holdings Inc (LNTH) Insider Michael P. Duffy Sells 11,492 Shares
www.americanbankingnews.com - March 16 at 8:15 PM |
| Lantheus Presents New Data on Novel Cardiac PET Imaging Agent LMI 1195 in Development for the Diagnostic Assessment of Ischemic Heart Failure Patients at Risk for Sudden Cardiac Death at ACC.18
finance.yahoo.com - March 12 at 10:58 AM |
| Lantheus (LNTH) Downgraded by BidaskClub
www.americanbankingnews.com - March 10 at 5:28 PM |
| Ranger Investment Management L.P. Acquires 4,230 Shares of Lantheus Holdings Inc (LNTH)
www.americanbankingnews.com - March 6 at 2:11 PM |
| Royce & Associates LP Sells 80,552 Shares of Lantheus Holdings Inc (LNTH)
www.americanbankingnews.com - March 6 at 10:52 AM |
| Tamarack Advisers LP Raises Stake in Lantheus Holdings Inc (LNTH)
www.americanbankingnews.com - March 6 at 10:30 AM |
| Lantheus Holdings Inc (LNTH) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 5 at 1:48 AM |
| Lantheus (LNTH) Downgraded to "Strong Sell" at Zacks Investment Research
www.americanbankingnews.com - March 4 at 9:12 AM |
| Bogle Investment Management L P DE Cuts Holdings in Lantheus Holdings Inc (LNTH)
www.americanbankingnews.com - March 3 at 4:52 AM |
| 320,411 Shares in Lantheus Holdings Inc (LNTH) Acquired by Arrowstreet Capital Limited Partnership
www.americanbankingnews.com - March 3 at 4:25 AM |
| Globeflex Capital L P Trims Position in Lantheus Holdings Inc (LNTH)
www.americanbankingnews.com - March 1 at 5:04 PM |
| Fuller & Thaler Asset Management Inc. Takes $1.82 Million Position in Lantheus Holdings Inc (LNTH)
www.americanbankingnews.com - March 1 at 10:50 AM |
| Q1 2018 Earnings Forecast for Lantheus Holdings Inc (LNTH) Issued By Jefferies Group
www.americanbankingnews.com - March 1 at 7:28 AM |
 | Bloomberg Markets: Macy’s Surprise Sales, Voyage Thru the Body
www.bloomberg.com - February 28 at 4:59 PM |
| EAM Investors LLC Acquires 11,910 Shares of Lantheus Holdings Inc (LNTH)
www.americanbankingnews.com - February 28 at 1:56 PM |
| Jefferies Group Comments on Lantheus Holdings Inc's Q2 2018 Earnings (LNTH)
www.americanbankingnews.com - February 28 at 9:18 AM |
| Lantheus Holdings Inc (LNTH) SVP Sells $72,367.68 in Stock
www.americanbankingnews.com - February 27 at 7:16 PM |
| Lantheus Holdings, Inc. Reports 2017 Fourth Quarter and Full Year Financial Results; Provides 2018 Guidance
finance.yahoo.com - February 27 at 9:30 AM |
| Lantheus Holdings Inc to Host Earnings Call
finance.yahoo.com - February 27 at 9:30 AM |
| Lantheus Holdings Appoints Gary Pruden, Kenneth Pucel and Dr. James Thrall to its Board of Directors
finance.yahoo.com - February 27 at 9:30 AM |
| Lantheus (LNTH) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS
www.americanbankingnews.com - February 26 at 9:16 PM |
| Systematic Financial Management LP Has $1.84 Million Stake in Lantheus Holdings Inc (LNTH)
www.americanbankingnews.com - February 25 at 11:38 AM |
| American Century Companies Inc. Has $3.78 Million Position in Lantheus Holdings Inc (LNTH)
www.americanbankingnews.com - February 24 at 4:12 AM |
| Lantheus Holdings Inc (LNTH) Expected to Announce Earnings of $0.16 Per Share
www.americanbankingnews.com - February 17 at 11:16 PM |
New England Nuclear (NASDAQ:LNTH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
New England Nuclear (NASDAQ:LNTH) Income Statement, Balance Sheet and Cash Flow Statement
New England Nuclear (NASDAQ LNTH) Stock Chart for Thursday, April, 26, 2018
Loading chart…
